NEW YORK (360Dx) – CellMax Life announced this week that it is beginning a new clinical trial, which will further validate its circulating tumor cell (CTC) colorectal cancer screening test in American subjects, with the goal of supporting a submission for approval by the US Food and Drug Administration.

The study is being conducted with a handful of medical centers, including Stanford Medicine, the US Department of Veterans Affairs, Johns Hopkins, and the University of Southern California.